Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
MWN-AI** Summary
Janux Therapeutics, Inc. (Nasdaq: JANX) released its financial results and business highlights for the fourth quarter and full year of 2025, marking significant progress in clinical developments and strategic collaborations. The company’s innovative immunotherapy pipeline continues to advance, particularly with its lead candidate, JANX007, which targets prostate-specific membrane antigen (PSMA) and is currently undergoing Phase 1 clinical trials in patients with metastatic castration-resistant prostate cancer (mCRPC).
During 2025, Janux made notable strides with JANX007, demonstrating robust safety profiles and measurable clinical activity in interim Phase 1 data, including high prostate-specific antigen (PSA) response rates. The company is also exploring JANX007 in combination therapies, targeting taxane-naïve mCRPC patients and offering hope for unmet medical needs. Additionally, JANX008 is advancing through clinical trials for solid tumors, while the initiation of a Phase 1 study of JANX011, examining healthy volunteers, underscores Janux's commitment to expanding its therapeutic reach.
A significant milestone was reached in January 2026, with Janux announcing a collaboration with Bristol Myers Squibb to develop a novel tumor-activated immunotherapy, providing potential near-term capital and expanding its strategic assets. Financially, Janux reported a year-end cash position of approximately $966.6 million, allowing for ongoing development efforts despite an increase in research and development expenses to $125.9 million for 2025.
Janux ended the year with a net loss of $113.6 million, reflecting increased operational investments to support its clinical pipeline. Moving into 2026, Janux remains focused on delivering clinical updates and leveraging its strong financial position to further enhance its immunotherapy portfolio. The appointment of William Go, M.D., Ph.D., as Chief Medical Officer is expected to bolster Janux's clinical leadership team as it continues to progress through anticipated milestones.
MWN-AI** Analysis
Janux Therapeutics, Inc. recently reported its fourth-quarter and full-year financial results for 2025, showcasing a year marked by strategic advancements and clinical progress. With a significant focus on its TRACTr platform, particularly with candidates JANX007 and JANX008, the firm is positioning itself favorably within the burgeoning immunotherapy landscape.
The collaboration with Bristol Myers Squibb (BMS) is a notable highlight, providing Janux with upfront and milestone payments that could total $850 million, a substantial boost to its financial position. This partnership indicates confidence in Janux's innovative tumor-activated therapies, suggesting strong potential for future value creation.
As of December 31, 2025, Janux maintained robust liquidity with $966.6 million in cash and short-term investments, despite a slight decrease from 2024. This capital should allow the company to fund ongoing clinical trials and research initiatives, pivotal for advancing their drug candidates through development phases. Investors should monitor the results from continued clinical activities, especially those related to JANX007 in metastatic castration-resistant prostate cancer (mCRPC), which has shown promising preliminary results.
While Janux's financial performance reflects significant R&D investments totaling $125.9 million for the year, which is indicative of its aggressive growth strategy, the escalating net loss of $113.6 million raises concerns about sustainable profitability in the near term. Investors need to weigh the company’s path toward commercialization against the backdrop of high expenditures typical in biotech.
In summary, Janux Therapeutics appears well-positioned for long-term success, driven by a robust capital base and strategic partnerships. However, prospective investors should remain cautious concerning financial outflows and the inherent uncertainties of clinical trials. Engaging with Janux's developments could be rewarding for those willing to take on the inherent risks linked with biotechnology investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Continued clinical execution across TRACTr programs JANX007 and JANX008
- JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC)
- JANX008 enrolling expansion cohorts in defined tumor settings
- Initiated Phase 1 study of JANX011 in healthy volunteers
- Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors
- Appointment of William Go, M.D., Ph.D., as Chief Medical Officer
- Strong year-end cash position supporting continued pipeline execution
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
“The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advances. Recent JANX007 clinical results demonstrate clinical activity and a consistent and predictable safety profile in mCRPC and support continued advancement in taxane-naïve patients as well as other expansion cohorts,” said David Campbell, Ph.D., President and CEO of Janux.
“In early 2026, we announced a collaboration with Bristol Myers Squibb that provides near-term capital and further validates the potential of our platform. We also continue to strengthen our team to support the next phase of clinical and pipeline growth. With additional product candidates entering the clinic in 2026, we believe Janux is well positioned to execute on our clinical strategy and continue to build long-term value for patients and shareholders.”
BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:
Clinical & Pipeline Progress
- Janux presented updated interim Phase 1 data for JANX007 (PSMA-TRACTr) in December 2025. As of the October 15, 2025 data cutoff, 109 patients had been treated across Phase 1 cohorts:
- Durable clinical activity was observed across both once-weekly (QW) and every-two-week (Q2W) cohorts, with median radiographic progression-free survival (rPFS) ranging from 7.9 to 8.9 months. The rPFS in the Q2W cohort compared favorably to the QW expansion group.
- Data demonstrated high prostate-specific antigen (PSA) response rates including deep PSA declines. Anti-tumor activity was observed, with confirmed and unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients.
- Ongoing dose optimization of JANX007 monotherapy is focused on taxane-naïve mCRPC.
- The Phase 1 study also includes expansion cohorts evaluating JANX007 in combination with darolutamide, an androgen receptor pathway inhibitor, to further characterize safety and clinical activity in taxane-naïve mCRPC.
- Additional expansion cohorts are evaluating JANX007 monotherapy in patients with PARP inhibitor-refractory mCRPC, supporting assessment of activity in a high-unmet-need population.
- JANX008 (EGFR-TRACTr) continues to enroll in its Phase 1 clinical trial in a defined group of solid tumors, with expansion cohorts underway to further characterize safety and clinical activity.
- JANX011 (CD19-ARM) is actively enrolling its Phase 1 clinical trial in healthy volunteers.
Strategic Collaboration
- In January 2026, Janux announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen.
- Under the terms of the agreement, Janux is eligible to receive $50 million in upfront and near-term milestone payments, with the potential for additional development, regulatory and commercial milestones totaling approximately $800 million, as well as tiered royalties on global product sales, if successful.
- Janux will lead preclinical development through IND submission, with Bristol Myers Squibb assuming responsibility for subsequent clinical development and global commercialization.
Corporate & Leadership
- Janux recently announced the appointment of William Go, M.D., Ph.D. as Chief Medical Officer, strengthening the Company’s clinical leadership as additional programs enter the clinic in 2026 and progress toward later-stage development.
Upcoming Milestones
- The Company expects to provide additional clinical data for JANX007 in 2026 or present these data at a future medical meeting.
- The Company expects to provide an additional clinical update for JANX008 in 2026.
- The Company expects to announce an initial clinical update from the Phase 1 study of JANX011 in healthy volunteers by year-end 2026.
FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS:
- Cash and cash equivalents and short-term investments: As of December 31, 2025, Janux reported cash and cash equivalents and short-term investments of $966.6 million, compared to $1.03 billion on December 31, 2024.
- Research and development expenses: Research and development expenses were $31.5 million for the quarter and $125.9 million for the year ended December 31, 2025, compared to $20.8 million and $68.4 million for the same quarter and year in 2024.
- General and administrative expenses: General and administrative expenses were $10.9 million for the quarter and $41.8 million for the year ended December 31, 2025, compared to $8.2 million and $41.0 million for the same quarter and year in 2024.
- Net loss: Net loss was $31.9 million for the quarter and $113.6 million for the year ended December 31, 2025, compared to $20.2 million and $69.0 million for the same quarter and year in 2024.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid tumors. Janux is also advancing its first ARM platform clinical candidate, JANX011, a CD19-ARM for the potential treatment of autoimmune diseases in a Phase 1 study in healthy adult volunteers. Janux continues to generate a number of additional TRACTr, TRACIr, and ARM programs for potential future development. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, and the potential benefits of Janux’s product candidates and platform technologies, expectations regarding the use of Janux’s platform technologies to generate novel product candidates and the strength of Janux’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov . Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Janux Therapeutics, Inc. Condensed Balance Sheets (in thousands) | ||||||
December 31, | December 31, | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 52,334 | $ | 430,605 | ||
Short-term investments | 914,233 | 594,568 | ||||
Prepaid expenses and other current assets | 9,320 | 8,493 | ||||
Total current assets | 975,887 | 1,033,666 | ||||
Restricted cash | 816 | 816 | ||||
Property and equipment, net | 3,852 | 4,864 | ||||
Operating lease right-of-use assets | 18,402 | 19,286 | ||||
Other long-term assets | 2,608 | 2,884 | ||||
Total assets | $ | 1,001,565 | $ | 1,061,516 | ||
Liabilities and Stockholders’ Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 4,971 | $ | 4,026 | ||
Accrued expenses | 17,633 | 11,684 | ||||
Current portion of operating lease liabilities | 2,393 | 1,749 | ||||
Total current liabilities | 24,997 | 17,459 | ||||
Operating lease liabilities, net of current portion | 19,746 | 21,276 | ||||
Total liabilities | 44,743 | 38,735 | ||||
Total stockholders’ equity | 956,822 | 1,022,781 | ||||
Total liabilities and stockholders’ equity | $ | 1,001,565 | $ | 1,061,516 |
Janux Therapeutics, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Collaboration revenue | $ | — | $ | — | $ | 10,000 | $ | 10,588 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 31,548 | 20,806 | 125,896 | 68,388 | ||||||||||||
General and administrative | 10,853 | 8,216 | 41,771 | 41,047 | ||||||||||||
Total operating expenses | 42,401 | 29,022 | 167,667 | 109,435 | ||||||||||||
Loss from operations | (42,401 | ) | (29,022 | ) | (157,667 | ) | (98,847 | ) | ||||||||
Total other income | — | 8,806 | — | 29,853 | ||||||||||||
Net loss | $ | (42,401 | ) | $ | (20,216 | ) | $ | (157,667 | ) | $ | (68,994 | ) | ||||
Other comprehensive gain (loss): | ||||||||||||||||
Unrealized gain (loss) on available-for-sale securities, net | 10,455 | (5,668 | ) | 44,042 | 1,498 | |||||||||||
Comprehensive loss | $ | (31,946 | ) | $ | (25,884 | ) | $ | (113,625 | ) | $ | (67,496 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.51 | ) | $ | (0.36 | ) | $ | (1.83 | ) | $ | (1.28 | ) | ||||
Weighted-average shares of common stock outstanding, basic and diluted | 62,145,668 | 56,832,374 | 61,966,999 | 53,751,480 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226553379/en/
Investors:
Chad Rubin
Endurance Advisors
crubin@enduranceadvisors.com
646.319.3261
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
FAQ**
How does Janux Therapeutics Inc. (JANX) plan to leverage its strong cash position of $966.6 million to advance its clinical programs, particularly JANX007 and JANX008?
What are the expected clinical outcomes for JANX007 in taxane-naïve mCRPC patients, and how does Janux Therapeutics Inc. (JANX) ensure the safety and efficacy of this treatment?
Can you elaborate on the collaboration between Janux Therapeutics Inc. (JANX) and Bristol Myers Squibb, and its potential impact on the development of new tumor-activated therapeutics?
What is the strategic significance of appointing William Go, M.D., Ph.D., as Chief Medical Officer for Janux Therapeutics Inc. (JANX), especially in light of upcoming clinical trials and pipeline expansion?
**MWN-AI FAQ is based on asking OpenAI questions about Janux Therapeutics Inc. (NASDAQ: JANX).
NASDAQ: JANX
JANX Trading
-0.87% G/L:
$13.65 Last:
293,292 Volume:
$13.67 Open:
